Gain Therapeutics, Inc. Cash Flow Statement
GANX|4 years of annual SEC 10-K data (FY2021-FY2024)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 4 fiscal years. All figures from audited SEC 10-K filings.
Gain Therapeutics, Inc. used $19M in operating cash flow and negative free cash flow of $19M in FY2024.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Net Income | -$22.3M | -$17.6M | -$13.9M | -$3.6M |
| Depreciation & Amortization | $83.6K | $64.2K | $15.5K | $9.6K |
| Operating Cash Flow | -$18.9M | -$14.7M | -$12.4M | -$3.2M |
| Capital Expenditures | $15.4K | $119.0K | $94.2K | $20.8K |
| Free Cash Flow | -$18.9M | -$14.8M | -$12.5M | -$3.3M |
| FCF Margin | -34217.5% | -10571.2% | -7551.7% | -11291.4% |